PPCB

Propanc Biopharma Inc

Jun 01 • 04:00PM ET

1.81

-0.01 -0.55 %

Healthcare • Biotechnology • Australia • Nano • NASD

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

Index	-	P/E	-	EPS (ttm)	-33.19	Insider Own	10.46%	Shs Outstand	2.28M	Perf Week	2.84%
Market Cap	4.12M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.04M	Perf Month	-28.74%
Enterprise Value	5.25M	PEG	-	EPS next Q	-	Inst Own	0.81%	Short Float	1.21%	Perf Quarter	-60.24%
Income	-19.29M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.18	Perf Half Y	-91.01%
Sales	0.00M	P/B	0.16	EPS next Y	-	ROA	-99.62%	Short Interest	0.02M	Perf YTD	-86.51%
Book/sh	11.24	P/C	9.36	EPS next 5Y	-	ROE	-131.52%	52W High	270.25 -99.33%	Perf Year	-96.78%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	98.29% 98.33%	ROIC	-169.10%	52W Low	1.56 16.35%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.99% 12.19%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	98.95%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.05	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.37	EPS Q/Q	97.73%	SMA20	-10.99%	Beta	3.30	Target Price	380.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-26.31%	Rel Volume	0.18	Prev Close	1.82
Employees	2	LT Debt/Eq	0.10	Earnings	-	SMA200	-92.07%	Avg Volume	139.64K	Price	1.81
IPO	Nov 12, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	25,584	Change	-0.55%

Today 05:30AM	Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain (GlobeNewswire)
May-20-26 08:45AM	Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade (GlobeNewswire) -12.22%
May-19-26 08:45AM	Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 - 40 Advanced Cancer Patients (GlobeNewswire)
May-15-26 08:45AM	Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results (GlobeNewswire) -6.98%
May-13-26 10:00PM	Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans (GlobeNewswire) -21.40%
10:30AM	Loading…
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +13.44%
Mar-24-26 08:45AM	Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaen and Granada, Spain (GlobeNewswire) -5.94%
Mar-12-26 08:45AM	Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy (GlobeNewswire) -13.57%
Mar-10-26 08:45AM	Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study (GlobeNewswire) -20.47%
Mar-03-26 08:45AM	Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models (GlobeNewswire) -5.16%
Feb-18-26 08:45AM	Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results (GlobeNewswire)
Feb-05-26 08:45AM	Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market (GlobeNewswire) +5.71%
Jan-27-26 08:45AM	Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations (GlobeNewswire) +6.52%
Jan-20-26 08:45AM	Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia (GlobeNewswire)
Jan-15-26 08:45AM	Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer (GlobeNewswire) -17.13%
08:45AM	Loading…
Jan-13-26 08:45AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Dec-22-25 07:00AM	Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal (GlobeNewswire) -8.45%
Dec-04-25 08:45AM	Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs (GlobeNewswire)
Dec-01-25 08:45AM	Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis (GlobeNewswire) +5.47%
Nov-17-25 08:45AM	Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results (GlobeNewswire)
Nov-10-25 08:45AM	Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline (GlobeNewswire) -12.43%
Nov-04-25 07:00AM	Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) (GlobeNewswire) -6.19%
Oct-15-25 05:45PM	CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire) -8.67%
08:45AM	Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire)
Oct-07-25 08:45AM	Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy (GlobeNewswire)
Sep-17-25 08:45AM	Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office (GlobeNewswire)
Sep-02-25 09:00AM	Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum (GlobeNewswire) -9.60%
Aug-25-25 07:30AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Aug-19-25 08:30AM	Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ (GlobeNewswire) -37.26%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +103.83%
11:00PM	Loading…
Aug-14-25 11:00PM	Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering (GlobeNewswire) +30.00% -72.40%

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

CEOJames Andrew Nathanielsz

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PPCB

Propanc Biopharma Inc

Upgrade your Finviz experience